king statements. Factors that could cause actual results to
differ materially include, but are not limited to, the Company's ability to
develop and introduce new products, differences in anticipated and actual
product and service introduction dates, the ultimate success of those
products in the marketplace, the continued acceptance and growth of current
products and services, the impact of competitive products and services, the
availability of sufficient quantities of suitable donated tissue and the
success of cost control and margin improvement efforts. Certain of these
factors are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission. All information in this
press release is as of May 1, 2008 and the Company does not intend to
update this information.
OSTEOTECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(dollars in thousands, except per share data)
Three Months
Ended March 31,
2008 2007
Revenue $ 27,631 $ 25,217
Cost of revenue 13,389 12,900
Gross profit 14,242 12,317
Marketing, selling and general and
administrative 11,680 11,690
Research and development 1,760 1,164
13,440 12,854
Operating income (loss) 802 (537)
Interest expense, net (212) (150)
Other 278 136
In
'/>"/>
SOURCE Osteotech, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference2.
Osteotech to Present at Sidoti Conference in San Francisco3.
Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule4.
Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 20075.
Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco6.
Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite7.
Osteotech to Present at the Sidoti Conference in New York8.
U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,1469.
Osteotech Announces First Quarter Earnings Release and Conference Call Schedule10.
Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance11.
Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine